Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Patients must give written informed consent before any assessment is performed.~2. Male, non-fertile female or female of childbearing potential using a medically approved birth control method based on local regulations.~3. Drug naïve type 2 diabetes patients, defined as who neither take consecutive anti-hyperglycemic drug treatment more than 3 months anytime, nor any anti-hyperglycemic drug treatment in 4 weeks prior to visit 1.~4. Age in the range of 18-75 years inclusive.~5. HbA1c in the range of \> 6.5 to ≤9.0% at Visit 1.~Exclusion criteria~1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/mL).~2. With known hypersensitivity to Nateglinide, Acarbose or any of the excipients.~3. A history of,~   1. type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.~  2. acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months.~  3. Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation.~  4. percutaneous coronary intervention within the past 3 months.~  5. any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery, unstable angina, or stroke.~4. Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy or gastroparesis.~5. Acute infections which may affect blood glucose control within 4 weeks prior to visit 1.~6. Congestive heart failure requiring pharmacologic treatment. mg/dL (123μmol/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nateglinide (Type: EXPERIMENTAL): Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
- Acarbose (Type: ACTIVE_COMPARATOR): Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).